Latigo Biotherapeutics
LTGO
58 hedge funds and large institutions have $697M invested in Latigo Biotherapeutics in 2026 Q3 according to their latest regulatory filings, with 58 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
62.97% more ownership
Funds ownership: 0% → 62.97% (+63%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5AM Venture Management
San Francisco,
California
|
+$155M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
+$112M |
| 3 |
Deep Track Capital
Greenwich,
Connecticut
|
+$93.1M |
| 4 |
Blue Owl Capital Holdings
New York
|
+$75.9M |
| 5 |
Foresite Capital Management V
Larkspur,
California
|
+$75.2M |
Top Sellers
LTGO Hedge Fund Activity: Q3 2026 in Review
58 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Latigo Biotherapeutics (LTGO) for Q3 2026, worth a combined $697M.
Buyers outnumbered sellers: 58 funds opened new LTGO positions and 0 closed out — a net gain of 58 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was 5AM Venture Management, opening a new position worth an estimated $155M.
- 58 institutional investors held Latigo Biotherapeutics (LTGO) as of Q3 2026, up from 0 in Q2 2026.
- Funds reported $697M of Latigo Biotherapeutics stock for Q3 2026.
- 58 funds opened new Latigo Biotherapeutics positions in Q3 2026 and 0 closed out, a net change of +58 holders.
- The largest Latigo Biotherapeutics buyer in Q3 2026 was 5AM Venture Management, an estimated $155M added.
Based on aggregated 13F filings for Q3 2026.